News

December 11, 2017

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine in adults. Galcanezumab has been submitted for use as a once-monthly, self-administered injection via ...

December 8, 2017

Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer
INDIANAPOLIS, Dec. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 RAINFALL study of CYRAMZA® (ramucirumab) in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the first-line treatment of patients with HER2-negative metastatic gastric or gastroesophageal junctio...

December 5, 2017

Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System
INDIANAPOLIS, Dec. 5, 2017 /PRNewswire/ -- Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by Eli Lilly and Company (NYSE: LLY). The AID system is part of the Connected Diabetes Ecosystem, which is being des...

December 1, 2017

Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
INDIANAPOLIS, Dec. 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).1 Taltz was first approved by the FDA in March 2016 for the treatment of adult patien...

November 13, 2017

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2017 /PRNewswire/ -- New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME...

November 9, 2017

New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
INDIANAPOLIS, Nov. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite of painful vertebral and non-vertebral fractures) compared with risedronate, a widely used oral bisphosphon...

November 8, 2017

ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
INDIANAPOLIS, Nov. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 wee...

November 5, 2017

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
INDIANAPOLIS, Nov. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements in pain control when compared to Humira®* (adalimumab) or placebo. A new post-hoc analysis of t...

October 30, 2017

Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting
INDIANAPOLIS, Oct. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif. Lilly will fe...

October 16, 2017

Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis
INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer in Y...

October 12, 2017

FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
INDIANAPOLIS, Oct. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor. The NDA was based upon the positive interim resul...

October 10, 2017

Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
INDIANAPOLIS, Oct. 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS)....

October 6, 2017

Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer
INDIANAPOLIS, Oct. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating VerzenioTM (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combination with a nonsteroidal aromatase inhibitor (NSAI) (anastrozole or letrozo...

October 4, 2017

Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib)
...

October 4, 2017

Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes
INDIANAPOLIS, Oct. 4, 2017 /PRNewswire/ -- Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (NYSE: LLY) offers for people with type 1 or type 2 diabetes. Humal...

September 14, 2017

Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of baricitinib in people with moderate-to-severe atopic dermatitis (AD). The results showed that baricitinib in combination with a mid-potency topical corticosteroid (...

September 12, 2017

Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 12, 2017 /PRNewswire/ -- New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study....

September 11, 2017

Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
INDIANAPOLIS, Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe...

September 10, 2017

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
INDIANAPOLIS, Sept. 10, 2017 /PRNewswire/ -- At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed results from the global, randomized, double-blinded, placebo-controlled RANGE ...

September 9, 2017

IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine
INDIANAPOLIS, Sept. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase 3 SPARTAN study. Detailed...

Showing 1-20 of 39 Page: 1 2  Next 20